
Release date: 2026-09-22 10:52:37 Article From: Lucius Laos Recommended: 33
The most common adverse reactions of Orforglipron are gastrointestinal effects—nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, abdominal distension, eructation, gastroesophageal reflux, and flatulence, as well as headache, fatigue, and alopecia. Most are mild to moderate in severity, most prominent during the dose titration period, and decrease over time.
Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and alopecia.
General pattern of side effects: The incidence of nausea, vomiting, and diarrhea is higher during the dose escalation phase and decreases over time. Higher doses generally correspond to a higher frequency of adverse events, though the relationship is not strictly linear.
The incidence of nausea increases from 26% at 5.5 mg to 35% at 17.2 mg, whereas constipation peaks at 27% with 9 mg and slightly decreases to 24% at 17.2 mg. This indicates that while the severity of reactions is related to dosage, individual variation remains significant.
Acute kidney injury, hypoglycemia, decreased blood pressure, tachycardia, diabetic retinopathy, and elevated pancreatic amylase and lipase.
Patients must strictly follow physician instructions to undergo regular monitoring of renal function, blood glucose, blood pressure, heart rate, and fundoscopic eye examinations.
1. Persistent or severe upper abdominal pain that may radiate to the back, with or without nausea and vomiting—acute pancreatitis should be suspected. If pancreatitis is suspected, discontinue treatment and seek medical care.
2. Severe or persistent gastrointestinal symptoms, such as intractable vomiting, severe diarrhea, or inability to tolerate oral intake of food and fluids—these represent severe gastrointestinal adverse reactions and warrant contacting a doctor.
3. Persistent or prolonged nausea, vomiting, or diarrhea, or signs such as marked thirst, decreased urine output, fatigue, or dizziness—acute kidney injury secondary to dehydration should be suspected, and reported to your doctor promptly.
4. Symptoms of hypoglycemia include: dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or somnolence, shakiness, weakness, headache, fast heartbeat, or restlessness. Risk is significantly increased, especially in patients using insulin or sulfonylureas. If these manifestations occur, manage them according to your doctor's pre-established instructions and report to your healthcare provider.
5. Swelling of the face, lips, tongue, or throat; fainting or dizziness; difficulty breathing or swallowing; rapid heart rate; or severe rash and itching—severe allergic reactions, including anaphylaxis and angioedema, should be suspected. Discontinue the medication and seek emergency medical care immediately.
6. Upper right abdominal pain, yellowing of the skin or whites of the eyes (jaundice), fever, or clay-colored stools—gallbladder disease should be suspected, and you should contact your doctor for gallbladder-related evaluations and follow-up.
7. Vision changes in diabetic patients—worsening of diabetic retinopathy should be suspected and reported to your doctor. Transient worsening of diabetic retinopathy has been reported following rapid improvements in blood glucose.
8. Planned surgery or procedures requiring general anesthesia or deep sedation—due to the risk of pulmonary aspiration during anesthesia, all medical personnel must be informed in advance. Postmarketing reports of pulmonary aspiration during elective procedures have occurred with this class of medications.
9. A mass or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath—thyroid tumors should be suspected, which fall under a boxed warning; report these symptoms to your physician immediately.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended:[list:visits]2026-30-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643